| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| WILSON TROY EDWARD | President and CEO, Director | C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO | Teresa Bair, Attorney-in-fact for Troy E. Wilson | 13 Aug 2025 | 0001589597 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | KURA | Common Stock | Purchase | $213,578 | +36,506 | +3771% | $5.85 | 37,474 | 12 Aug 2025 | Direct | F1, F2 |
| transaction | KURA | Common Stock | Purchase | $89,623 | +13,494 | +36% | $6.64 | 50,968 | 13 Aug 2025 | Direct | F3 |
| holding | KURA | Common Stock | 279,194 | 12 Aug 2025 | by One Fish Two Fish Revocable Trust | ||||||
| holding | KURA | Common Stock | 300,000 | 12 Aug 2025 | by Lorax Charitable Remainder Unitrust |
| Id | Content |
|---|---|
| F1 | This transaction was executed in multiple trades at prices ranging from $5.56 to $5.995. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| F2 | Includes 409 shares acquired on May 17, 2024 pursuant to the Issuer's Employee Stock Purchase Plan. |
| F3 | This transaction was executed in multiple trades at prices ranging from $6.485 to $6.735. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |